We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urinary Markers Predict Bone Problems after Hip Replacement

By LabMedica International staff writers
Posted on 20 Jun 2018
Osteolysis is an active resorption of bone matrix by osteoclasts and can be interpreted as the reverse of ossification. More...
Although osteoclasts are active during the natural formation of healthy bone the term "osteolysis" specifically refers to a pathological process.

Peri‐implant osteolysis is commonly diagnosed after substantial bone loss has occurred, making revision surgery more challenging. A method has been developed was to identify urinary biomarkers that differentiate total hip replacement patients who eventually develop osteolysis from patients who do not.

Scientists at Rush University Medical Center (Chicago, IL, USA) used a repository of 24‐hour urine samples collected prior to surgery and annually thereafter in 26 patients, 16 who developed osteolysis, and 10 who did not. They examined the markers at radiographic diagnosis, annually for six years preceding diagnosis, at the first post‐operative sampling point, and pre‐operatively. Patients in the osteolysis and non‐osteolysis groups were matched according to time post‐surgery and did not differ in the male:female ratio or age at surgery.

The team measured seven candidate biomarkers, including free deoxypyridinoline (DPD), cross‐linked N‐telopeptides (NTX), interleukin‐6 (IL‐6), interleukin‐8 (IL‐8), osteoprotegerin (OPG), α‐crosslaps (α‐CTX), and β‐crosslaps (β‐CTX). The scientists found that as an individual biomarker, DPD demonstrated the highest ability to predict osteolysis, with an area under the curve (AUC) in Receiver Operating Characteristic (ROC) analyses of 0.844 at six years prior to diagnosis. A panel of α‐CTX and IL‐6 was able to identify at‐risk patients with an AUC of 0.941 or greater at all post‐operative time points and an AUC of 1.000 pre‐operatively.

The authors concluded that their results demonstrate the potential of using non‐invasive biomarkers to identify patients at risk for peri‐implant osteolysis long before the emergence of radiographic signs. Further, the high accuracy of the pre‐operative biomarker levels demonstrates the potential importance of pre‐existing, patient‐specific factors driving subsequent osteolysis. The study was published on June 5, 2018, in the Journal of Orthopaedic Research.

Related Links:
Rush University Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.